SCHEMBL6824158

SCHEMBL6824158

COCCOc1c(C(=O)NCCN)cc2ccccc2c1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD3 P35462 3/20 0.52
▸ MAOB P27338 1/20 0.45
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.42
▸ GAA P10253 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HPGD P15428 2/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824612 0.78 CDC25B (0.45) DRD3MAOBKMT2AKDM4EMEN1
SCHEMBL6825155 0.72 ALDH1A1 (0.47) KMT2AKDM4EMEN1POLBMAPT
SCHEMBL8183672 0.72 HPGD (0.55) DRD3KMT2AKDM4EMAPTALDH1A1
SCHEMBL6824550 0.68 CDC25B (0.47) MAOBKMT2AKDM4EMEN1ALDH1A1
SCHEMBL30617721 0.68 KDM4E (0.50) MAOBKMT2AKDM4EMEN1ALDH1A1
SCHEMBL13873445 0.68 KDM4E (0.50) MAOBKMT2AKDM4EMEN1ALDH1A1
SCHEMBL1913803 0.68 HPGD (0.64) MAOBKMT2AMEN1ALDH1A1HPGD
SCHEMBL14664422 0.68 KMT2A (0.62) KMT2AMEN1MAPTALDH1A1L3MBTL1
SCHEMBL6824265 0.68 TSHR (0.47) KMT2AKDM4EMEN1ALDH1A1GAA
SCHEMBL23271878 0.67 GPR84 (0.44) KMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 — — US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 — — EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 — — EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 — — US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 — — WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R DRD3 4017/4885MAOB 3608/4885KMT2A 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback